Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3931)	6/2/2004 9:53:57 AM
From: rkrw	Read Replies (1) \| Respond to of 4974

<<What the heck does everyone expect? In the good old days, before underwriters dictated what will and will not sell, we got good companies going public.... the type of company that analysts tell one not to buy.... companies with great science and no clue. DNA and AMGN couldn't make it out today. So what do we get? We get a bunch of companies with also-ran, licensed crap, but it's in advanced testing!!>>> Seems all the rage at vc's is inlicense anything and then go public. No patience for nuts and bolts innovative r&d. Don't know anything specific but I've heard some good things about these guys (recent ipo)... Press Release Source: Cytokinetics, Inc. Cytokinetics Announces Phase I Results for SB-715992 to be Presented at the 2004 Annual Meeting of the American Society of Clinical Oncology Wednesday June 2, 8:02 am ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 2, 2004--Cytokinetics, Inc. (Nasdaq: CYTK - News) announced today that the results of two Phase I studies for SB-715992 conducted by GlaxoSmithKline will be presented at the 2004 Annual Meeting of the American Society of Clinical Oncology (ASCO) in New Orleans. These oral and poster presentations focus on the safety and tolerability of SB-715992, a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin protein essential for proper cell division. SB-715992 is the lead drug candidate in clinical development arising from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline has initiated a broad Phase II clinical trial program for SB-715992. Abstracts being presented These abstracts will be available upon request or through the ASCO website (www.asco.org): 1. Abstract #2004: Phase I Trial of Novel Kinesin Spindle Protein (KSP) Inhibitor SB-715992 IV days 1, 8, 15 Q 28 Days. (Oral presentation by Howard A. Burris III, The Sarah Cannon Cancer Center, Nashville, TN, on Sunday, June 6, 2004, Hall I1, 7:45 AM - 10:45 AM). 2. Abstract #2078: Phase I Trial of Novel Kinesin Spindle Protein (KSP) Inhibitor SB-715992 IV Q 21 Days. (Poster presentation by Quincy S. Chu, Cancer Therapy & Research Center (CTRC), San Antonio, TX, on Monday, June 7, 2004, Hall A (right half), 8:00 AM - 12:00 PM). About Cytokinetics Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA(TM) system and Cytometrix(TM) technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and are thereby less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II clinical trials for SB-715992 and a Phase I clinical trial with SB-743921, each a drug candidate that has emerged from the strategic alliance. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.